Fiche publication
Date publication
juillet 2025
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAIS DE BARROS Jean-Paul
Tous les auteurs :
Tume R, El Sherbiny S, Bono R, Gautier T, Pais de Barros JP, Meroño T
Lien Pubmed
Résumé
Lipopolysaccharide (LPS) from Gram-negative bacteria has been one of the most studied pathogen-associated molecular patterns triggering rapid inflammatory reactions. However, evidence shows that not all LPS molecules are proinflammatory ("bad"), and that "good" LPS from gut commensal bacteria exert immunomodulatory actions. The Limulus amebocyte lysis test commonly used to quantify LPS in circulation, only targets "bad" LPS, when not inactivated by plasma components. Use of other methods showed healthy subjects featuring elevated levels of LPS (suggesting predominance of "good" or inactive LPS in circulation). This review aims to summarize the evidence supporting the higher abundance of "good" LPS coming from gut commensals of healthy individuals and their potential impact in human health.
Mots clés
gut microbiota, inflammation, intestinal permeability, lipopolysaccharide (endotoxin), nutrition
Référence
Front Immunol. 2025 07 9;16:1588129
